Phase I study of diaziquone.


Twenty-eight patients received diaziquone (AZQ) as a single iv dose ranging from 2 to 27.5 mg/m2 in a phase I study. Myelosuppression was dose-limiting, tended to be cumulative, and was somewhat unpredictable in its occurrence. No pretreatment patient characteristics or chemical abnormalities were found to be consistently related to hematologic toxicity. No… (More)


Cite this paper

@article{Frytak1984PhaseIS, title={Phase I study of diaziquone.}, author={Stephen Frytak and Robert T. Eagan and Matthew Ames and Edward T. Creagan and William C. Nichols}, journal={Cancer treatment reports}, year={1984}, volume={68 7-8}, pages={975-8} }